Photosensitive epilepsy

TheraSpecs® Announces Groundbreaking New Product Lines to Tackle Brain Injuries, Epilepsy, and More

Retrieved on: 
Thursday, December 7, 2023
Brain, Sleep, Migraine, Research, Catalog, Lens, Photosensitive epilepsy, Headache, Concussion, Multimedia, Light, Health, Seizure, Photophobia, GLARE, Epilepsy, Insomnia, Flex, Post-concussion syndrome, Telescopic sight, Camera, PHOENIX

PHOENIX, Dec. 7, 2023 /PRNewswire-PRWeb/ -- TheraSpecs® Company, the leading brand of therapeutically tinted glasses for migraine and light sensitivity, today announced multiple new product lines designed for a wide range of additional symptoms, conditions, and situations. As the first company to offer such a line direct to consumers, TheraSpecs is positioned to help millions with brain injuries, photosensitive epilepsy, insomnia, and computer headaches.

Key Points: 
  • As the first company to offer such a line direct to consumers, TheraSpecs is positioned to help millions with brain injuries, photosensitive epilepsy, insomnia, and computer headaches.
  • "I started TheraSpecs in 2011 to help my wife and people like her with debilitating chronic migraine," said founder and CEO, Hart Shafer.
  • They've been made even better with the addition of premium optical coatings that further reduce scratches, smudges, and glare.
  • These are hands down the best product I have ever invested in and my overall health and well-being has been positively impacted!"

Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST)

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Cannabis, Clinical Trials, Other Health, MD, Epilepsy, CEO, RLS, Child, Clinical trial, Psychiatry, IND, Photosensitive epilepsy, Trial of the century, New York University Grossman School of Medicine, Neurological disorder, Epilepsy Foundation, FDA, Seizure, REST, Patient, Central nervous system, Pharmaceutical industry, CBD, Neurology, Neurosurgery, Medicine

A proof-of-concept clinical safety and efficacy study in epilepsy will be conducted under a second, recently opened IND application.

Key Points: 
  • A proof-of-concept clinical safety and efficacy study in epilepsy will be conducted under a second, recently opened IND application.
  • The Phase 1b randomized, double-blind, placebo-controlled, crossover study will evaluate RLS103 in patients with photosensitive epilepsy as a model for REST.
  • RLS103, a dry powder inhaled cannabidiol (CBD), is a first-in-class drug/device combination product for the acute treatment of psychiatric and neurological disorders.
  • For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval, see www.receptorlife.com .

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Retrieved on: 
Monday, July 18, 2022
SEC, Photosensitive epilepsy, PAM, Patient, LinkedIn, CMC, Nasdaq, Safety, Epilepsy, GABAA, Therapy, Review, Homeostasis, GLOBE, PMD, Chronic pain, IND, Lists of diseases, COVID-19, Company, PEA, KV7, MDD, Compliance, Psychiatry, Disorder, Neuron, Chemistry, Pharmaceutical industry, PSE

SEATTLE and CAMBRIDGE, United Kingdom, July 18, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today provided an update on its plans to advance its ETX-155 clinical program.

Key Points: 
  • ETX-155 is a novel, neuroactive steroid GABAA receptor positive allosteric modulator (PAM) that the Company plans to evaluate in subjects with major depressive disorder (MDD), perimenopausal depression (PMD), and epilepsy.
  • Evaluation and implementation of CMC process modifications to ensure consistency of drug product manufacturing are currently underway.
  • In parallel, the Company plans to initiate a Phase 1 pharmacokinetic trial in healthy subjects using the drug batches that were used in the Phase 1b PSE trial.
  • At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

Eliem Therapeutics Reports First Quarter Financial and Business Highlights

Retrieved on: 
Monday, May 16, 2022
PEA, Research and development, Lists of diseases, Pain, Company, MDD, Root cause analysis, R, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, G&A, Food, Nasdaq, Patient, Homeostasis, Disorder, Review, Therapy, Psychiatry, COVID-19, Epilepsy, Depression, GABAA, FDA, Neuron, IND, PMD, Compliance, Program, GAD, Safety, Chronic pain, Photosensitive epilepsy, Administration, SEC, Sciatica, GLOBE, Risk, Pharmaceutical industry

We are excited about the potential of our pipeline in multiple neuronal excitability disorders, said Bob Azelby, president and chief executive officer of Eliem Therapeutics.

Key Points: 
  • We are excited about the potential of our pipeline in multiple neuronal excitability disorders, said Bob Azelby, president and chief executive officer of Eliem Therapeutics.
  • The Company announced the completion of enrollment of the LSRP Phase 2a trial in April 2022, with topline data expected inthe third quarter of2022.
  • At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
  • Additional information will also be set forth in Eliem's other reports and filings it will make with the SEC from time to time.

Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs

Retrieved on: 
Monday, April 25, 2022
Lists of diseases, Neuropathic pain, PEA, MDD, IND, COVID-19, GABAA, PMD, Annual report, Anxiety, Neuron, Compliance, Photosensitive epilepsy, GLOBE, Risk, Patient, Placebo, LinkedIn, Review, Pain, Nasdaq, Chronic pain, PSE, Depression, SEC, KV7, Safety, Disorder, Epilepsy, Sciatica, Psychiatry, Therapy, Homeostasis, Pharmaceutical industry

SEATTLE and CAMBRIDGE, United Kingdom, April 25, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported results from its Phase 2a clinical trial investigating ETX-810 for the treatment of diabetic peripheral neuropathic pain (DPNP), and provided an update on the status of the ETX-155 clinical program in epilepsy and depression.

Key Points: 
  • We are obviously disappointed with the results of this proof-of-concept trial of ETX-810, said Bob Azelby, president and chief executive officer of Eliem.
  • We sincerely thank the patients who participated in this trial, along with the investigators, clinical staff, and Eliem team who managed the study.
  • The multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial ( NCT04688671 ) evaluated the efficacy and safety of ETX-810 in 159 subjects with DPNP over four weeks of dosing.
  • Last month, the company received clearance to proceed with an IND to progress ETX-155 in Phase 2a clinical trials in depression.

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights

Retrieved on: 
Monday, March 7, 2022
Administration, Lists of diseases, Neuron, PEA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, PSE, Food, Polypharmacy, Safety, Annual report, GABAA, FDA, Program, Therapy, Drug discovery, Homeostasis, Company, SEC, Epilepsy, COVID-19, Research and development, Chronic pain, Pain, Compliance, Acquisition, Photosensitive epilepsy, Sciatica, MDD, IND, Risk, Review, R, Investigational New Drug, PMD, Psychiatry, Disorder, GAD, Nasdaq, GLOBE, Depression, Pharmaceutical industry, Lithium

SEATTLE and CAMBRIDGE, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported financial results and business highlights for the quarter and year ended December 31, 2021.

Key Points: 
  • Completed dosing in our Phase 2a clinical trial evaluating ETX-810 in subjects with diabetic peripheral neuropathic pain (DPNP).
  • The Company has completed dosing for its Phase 2a clinical trial evaluating the efficacy and safety of ETX-810 in subjects with DPNP.
  • The Company remains on track to announce topline data from this trial in the first half of 2022.
  • Additional information will also be set forth in Eliem's other reports and filings it will make with the SEC from time to time.

Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones

Retrieved on: 
Tuesday, January 18, 2022
Patient, Epilepsy, Conference, PSE, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, GABAA, PMD, MDD, Sciatica, Safety, Risk, GLOBE, Chronic pain, IND, Review, Psychiatry, Nasdaq, Lists of diseases, Pain, Homeostasis, Therapy, Program, Company, Disorder, Depression, Neuron, Food, FDA, Compliance, GAD, Photosensitive epilepsy, Pharmaceutical industry

SEATTLE and CAMBRIDGE, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today is providing program updates and announcing expected milestones.

Key Points: 
  • The Company is continuing the preclinical development of this program with the intent to provide a development plan update later in 2022.
  • Eliem will present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022 being held February 14-18.
  • Eliem channels its experience, energy, and passion for improving patients quality of life to fuel our efforts to develop life-changing novel therapies.
  • At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Retrieved on: 
Monday, November 8, 2021
Compliance, Safety, FOS, Neuron, G&A, Therapy, Psychiatry, Disorder, Epilepsy, Somnolence, Clinical trial, MDD, R, Depression, PSE, Chronic pain, Administration, COVID-19, GABAA, PAM, Photosensitive epilepsy, Program, Risk, CNS, Arousal, Incidence, Research and development, Pain, Company, GAD, GLOBE, Homeostasis, SEC, Sciatica, Central nervous system, Nasdaq, Patient, PMD, Literature, IND, Pharmaceutical industry

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported financial results and business highlights for the quarter ended September 30, 2021.

Key Points: 
  • Completed 14-day repeat dose Phase 1 study demonstrating ETX-155 was well tolerated with an approximate 40-hour half-life supporting once-daily dosing.
  • The study also confirmed that ETX-155 was generally well tolerated with no severe or serious adverse events, or discontinuations.
  • At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
  • Additional information will also be set forth in Eliem's other reports and filings it will make with the SEC from time to time.

Global Epilepsy Pipeline Landscape Report 2021: Comprehensive Insights for 70+ Companies and 70+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021
Health, Pharmaceutical, A2, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CNS, Clinical trial, News, Protocol, Therapy, ODD, COMP, IDH1, Pharmacokinetics, IIA, Lists of diseases, II, Review, Research, Mergers and acquisitions, Channel modulator, PAM, Central nervous system disease, Cannabidiol, Committee, European Medicines Agency, GW Pharmaceuticals, A3, FDA, Fast Track, Patient, GABAA, Adult, Lennox–Gastaut syndrome, Ganaxolone, Ageing, Lorazepam, Status epilepticus, KCNQ2, Photosensitive epilepsy, ES, Dravet syndrome, Safety, Seizure, Lists of World Heritage Sites, GABAergic, A5, EMA, Discovery, Pharmaceutical industry

This Epilepsy - Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Key Points: 
  • This Epilepsy - Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Epilepsy R&D.
  • The therapies under development are focused on novel approaches to treat/improve Epilepsy.
  • This segment of the Epilepsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

Eliem Therapeutics Reports Second Quarter Financial Results

Retrieved on: 
Monday, September 13, 2021
FOS, G&A, Chronic pain, Therapy, Photosensitive epilepsy, Initial public offering, R, PMD, Research and development, IPO, Depression, Neuron, Patient, Â, Company, GABAA, Homeostasis, Safety, MDD, COVID-19, Major depressive disorder, Administration, Neuroinflammation, Lists of diseases, Pain, Epilepsy, GLOBE, Psychiatry, PEA, Compliance, Risk, GAD, Sciatica, SEC, Disorder, Exercise, Security (finance), Pharmaceutical industry, Vaccine

SEATTLE and CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported financial results and business highlights for the quarter ended June 30, 2021.

Key Points: 
  • In the second quarter, we continued to advance enrollment on our two Phase 2a studies for ETX-810 in patients with chronic pain conditions.
  • The IPO was preceded by a Series B financing in May 2021 that raised gross proceeds of $60.0 million.
  • At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
  • Additional information will also be set forth in Eliem's other reports and filings it will make with the SEC from time to time.